Genmab A (GMAB) Prepaid Assets (2023 - 2025)
Genmab A's (GMAB) quarterly Prepaid Assets came in at $65.0 million in Q4 2025, up 172.89% on a YoY basis from $23.8 million in Q4 2024, and up 172.89% quarter-over-quarter from $23.8 million in Q4 2024.
Analysis
Genmab A (GMAB) Prepaid Assets (2023 - 2025) Analysis & Trends
Genmab A (GMAB) has reported Prepaid Assets for 3 consecutive years, with $65.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Prepaid Assets rose 172.89% year-over-year to $65.0 million; the trailing twelve-month figure through Dec 2025 stood at $65.0 million (up 172.89% YoY), and the FY2025 full-year result was $65.0 million, up 172.89% from the prior year.
- Prepaid Assets rose to $65.0 million in Q4 2025 per GMAB's latest filing, from $23.8 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $65.0 million in Q4 2025 and bottomed at $22.6 million in Q4 2023.
- Historically, Prepaid Assets has averaged $37.2 million across 3 years, with a median of $23.8 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets climbed 5.2% in 2024, then surged 172.89% in 2025.
- Over 3 years, Prepaid Assets stood at $22.6 million in 2023, then climbed by 5.2% to $23.8 million in 2024, then soared by 172.89% to $65.0 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $65.0 million, $23.8 million, and $22.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 65.00 Mn |
| Dec 31, 2024 | 23.82 Mn |
| Dec 31, 2023 | 22.64 Mn |